CH0012005267

Novartis bolsters late-stage cardiovascular pipeline with agreement to acquire Anthos Therapeutics for USD 925 million upfrontNovartis bolsters late-stage cardiovascular pipeline with agreement to acquire Anthos Therapeutics for USD 925 million upfront

Novartis bolsters late-stage cardiovascular pipeline with agreement to acquire Anthos Therapeutics for USD 925 million upfront

Anthos Therapeutics is a clinical-stage biopharmaceutical company developing abelacimab, a potential first-in-class monoclonal antibody targeting the FXI inhibition pathwayAbelacimab is…

1 week ago
Novartis continues strong momentum of sales growth with margin expansion, reaches key innovation milestones in 2024Novartis continues strong momentum of sales growth with margin expansion, reaches key innovation milestones in 2024

Novartis continues strong momentum of sales growth with margin expansion, reaches key innovation milestones in 2024

Ad hoc announcement pursuant to Art. 53 LRFull yearNet sales grew +12% (cc1, +11% USD) with core operating income1 up…

3 weeks ago
Longer-term data for Novartis Scemblix reinforce superior efficacy with favorable safety and tolerability profile in adults with newly diagnosed CMLLonger-term data for Novartis Scemblix reinforce superior efficacy with favorable safety and tolerability profile in adults with newly diagnosed CML

Longer-term data for Novartis Scemblix reinforce superior efficacy with favorable safety and tolerability profile in adults with newly diagnosed CML

Scemblix demonstrated sustained superior major molecular response (MMR) vs. all investigator-selected TKIs (74.1% vs. 52%) and vs. imatinib alone (76.2%…

2 months ago
New Phase IIIB data shows Novartis Fabhalta improved hemoglobin levels in adult patients with paroxysmal nocturnal hemoglobinuria who switched from anti-C5 therapyNew Phase IIIB data shows Novartis Fabhalta improved hemoglobin levels in adult patients with paroxysmal nocturnal hemoglobinuria who switched from anti-C5 therapy

New Phase IIIB data shows Novartis Fabhalta improved hemoglobin levels in adult patients with paroxysmal nocturnal hemoglobinuria who switched from anti-C5 therapy

In the Phase IIIB APPULSE-PNH study, oral Fabhalta® (iptacopan) improved the average hemoglobin (Hb) level versus baseline in adult patients…

3 months ago
Novartis upgrades mid-term guidance and highlights deep pipeline in core therapeutic areas to drive long-term growthNovartis upgrades mid-term guidance and highlights deep pipeline in core therapeutic areas to drive long-term growth

Novartis upgrades mid-term guidance and highlights deep pipeline in core therapeutic areas to drive long-term growth

Ad hoc announcement pursuant to Art. 53 LR Mid-term sales guidance upgraded to +6% CAGR 2023-2028 and +5% 2024-2029Strong momentum…

3 months ago